UB Paderborn / Katalog / Suche / in CDI

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice

Endocrinology (Philadelphia), 2016-03, Vol.157 (3), p.1029-1042

2016

Volltextzugriff (PDF)

Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice

The Journal of pharmacology and experimental therapeutics, 2012-06, Vol.341 (3), p.692

2012

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects

Drug research, 2017-06, Vol.67 (6), p.349

2017

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats

Drug metabolism and disposition, 2011-10, Vol.39 (10), p.1801

2011

Volltextzugriff (PDF)

Discovery of Tofogliflozin, a Novel C‑Arylglucoside with an O‑Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Journal of medicinal chemistry, 2012-09, Vol.55 (17), p.7828-7840

2012

Volltextzugriff (PDF)

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

American journal of physiology: endocrinology and metabolism, 2013-02, Vol.304 (4), p.E414-E423

2013

Volltextzugriff (PDF)

In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach

The Journal of pharmacology and experimental therapeutics, 2013-04, Vol.345 (1), p.52

2013

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Modeling for the Effect of Sodium–Glucose Cotransporter Inhibitors on Blood Glucose Level and Renal Glucose Excretion in db/db Mice

Journal of pharmaceutical sciences, 2012-11, Vol.101 (11), p.4347-4356

2012

Volltextzugriff (PDF)

In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

Xenobiotica, 2015-03, Vol.45 (3), p.230-238

2015

Volltextzugriff (PDF)

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Bioorganic & medicinal chemistry, 2012-07, Vol.20 (13), p.4117-4127

2012

Volltextzugriff (PDF)

Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation

Nature medicine, 1999-05, Vol.5 (5), p.560-564

1999

Volltextzugriff (PDF)

5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Bioorganic & medicinal chemistry, 2011-09, Vol.19 (18), p.5334-5341

2011

Volltextzugriff (PDF)

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

American journal of physiology: endocrinology and metabolism, 2013, Vol.67 (2)

2013

Volltextzugriff (PDF)

C-Aryl 5a-carba-I2-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Bioorganic & medicinal chemistry, 2012-07, Vol.20 (13), p.4117-4127

2012

Volltextzugriff (PDF)

5a-Carba-[beta]-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Bioorganic & medicinal chemistry, 2011-09, Vol.19 (18), p.5334-5341

2011

Volltextzugriff (PDF)

The Decrement of Muscarinic Receptor-Mediated Calcium Influx by Overexpression of APP in a Mouse Cholinergic Cell Line

The Tohoku Journal of Experimental Medicine, 1994, Vol.174(3), pp.225-239

1994

Volltextzugriff (PDF)

Oxidized low density lipoprotein caused CNS neuron cell death

Brain research, 1997-06, Vol.761 (1), p.165-172

1997

Volltextzugriff (PDF)

Secretion kinetics of Alzheimer's amyloid beta-protein differs from secreted beta-amyloid precursor protein

Biochemical and biophysical research communications, 1995-09, Vol.214 (2), p.490-495

1995

Volltextzugriff (PDF)

Demonstration of amyloid β-protein secretion in a mouse neuronal cell line

Neuroscience letters, 1994-02, Vol.167 (1), p.125-127

1994

Volltextzugriff (PDF)

Polyclonal Antibodies to DNA Modified with 4‐Nitroquinoline 1‐Oxide: Application for the Detection of 4‐Nitroquinoline 1‐Oxide‐DNA Adducts in vivo

Cancer science, 1988-02, Vol.79 (2), p.195-203

1988

Volltextzugriff (PDF)

Spectrophotometrical and immunochemical studies on the conformational changes in poly(dG-dC) · poly(dG-dC) after modification by 4-hydroxyaminoquinoline 1-oxide

Biochimica et biophysica acta. Gene structure and expression, 1991-08, Vol.1090 (1), p.29-37

1991

Volltextzugriff (PDF)

Behavior of fluorine on silicon (100) surfaces etched with NH sub(4)F aqueous solutions

Electronics & communications in Japan. Part 2, Electronics, 2000-07, Vol.83 (7), p.41-47

2000

Volltextzugriff (PDF)

Behavior of fluorine on silicon (100) surfaces etched with NH4F aqueous solutions

Electronics & communications in Japan. Part 2, Electronics, 2000-07, Vol.83 (7), p.41-47

2000

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice

Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice

Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects

Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats

Discovery of Tofogliflozin, a Novel C‑Arylglucoside with an O‑Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach

Pharmacokinetic and Pharmacodynamic Modeling for the Effect of Sodium–Glucose Cotransporter Inhibitors on Blood Glucose Level and Renal Glucose Excretion in db/db Mice

In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation

5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

C-Aryl 5a-carba-I2-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

5a-Carba-[beta]-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

The Decrement of Muscarinic Receptor-Mediated Calcium Influx by Overexpression of APP in a Mouse Cholinergic Cell Line

Oxidized low density lipoprotein caused CNS neuron cell death

Secretion kinetics of Alzheimer's amyloid beta-protein differs from secreted beta-amyloid precursor protein

Demonstration of amyloid β-protein secretion in a mouse neuronal cell line

Polyclonal Antibodies to DNA Modified with 4‐Nitroquinoline 1‐Oxide: Application for the Detection of 4‐Nitroquinoline 1‐Oxide‐DNA Adducts in vivo

Spectrophotometrical and immunochemical studies on the conformational changes in poly(dG-dC) · poly(dG-dC) after modification by 4-hydroxyaminoquinoline 1-oxide

Behavior of fluorine on silicon (100) surfaces etched with NH sub(4)F aqueous solutions

Behavior of fluorine on silicon (100) surfaces etched with NH4F aqueous solutions

Suchergebnisse filtern